DSIpharma, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-10-02.
DSIpharma, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on October 2, 2026. The filing reports $951K sold. Its industry group is Other Health Care. It names Mark Ridall (Executive Officer, Director), Kysha Pierre-Louis (Executive Officer, Director) (SEC Form D/A, October 2, 2026).
Is this your company?
Sell to companies like DSIpharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-02 · the record
Pitching, partnering or investing alongside them? See who really runs and owns DSIpharma, Inc.
Free to see. No signup.
More on the people and the money behind DSIpharma, Inc., from the filings we hold.
Other Health Care raises by companies based in Delaware, filed within 90 days of this one, largest first.
Get an email when DSIpharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when DSIpharma, Inc. raises, hires or launches. No email unless you switch it on.
Watch DSIpharma, Inc. →Get the full cited report on DSIpharma, Inc.
What the filing shows about DSIpharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on DSIpharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives DSIpharma, Inc.'s address as 251 Little Falls Drive, Wilmington, DE 19808.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for DSIpharma, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
DSIpharma, Inc. is a registered filer with the SEC (CIK 2076369) and has filed since 2025-07-15. 1 filing is on record, the latest on 2025-07-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
DSIpharma, Inc.'s Form D of 2026-10-02 names Mark Ridall and Kysha Pierre-Louis as its officers, directors or promoters.
Its new offerings report $45K sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 866 filings in Other Health Care, totalled by week. The dot is this raise, $951K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Mark Ridall is named as Executive Officer and Director on the Form D that DSIpharma, Inc. filed with the SEC on 2 October 2026, one of 2 people that filing names.
Kysha Pierre-Louis is named as Executive Officer and Director on the Form D that DSIpharma, Inc. filed with the SEC on 2 October 2026, one of 2 people that filing names.
2 people named on the filing — 2 holding an executive role.
Named as of the 2026-10-02 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about DSIpharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on DSIpharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DSIpharma, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist DSIpharma, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind DSIpharma, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for DSIpharma, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/dsipharma-inc-form-d-000002